^
Association details:
| Biomarker: | KIT S628N |
|---|---|
| Cancer: | Melanoma |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel KIT Mutation Found in a Metastatic Melanoma
Excerpt:
We report a novel KIT gain-of-function mutation with S628N substitution (exon 13) and show that it is sensitive to imatinib in vitro....We tested 2 KIT inhibitors: imatinib and dasatinib. Both inhibitors abolished the autophosphorylation of KIT S628N at a moderate concentration...We concluded that KIT S628N mutant is sensitive to imatinib and dasatinib.
DOI:
10.1001/jamadermatol.2014.1437
